RESUMO
Routine cytogenetic analysis frequently fails to identify an abnormal clone in B-cell lymphocytic leukemia [B-CLL] due to poor response to mitogen stimulation. Fluorescence in situ hybridization [FISH] suggest that chromosomal abnormalities occur more frequently, most commonly trisomy 12, retinoblastoma gene deletion [Rb 1 gene] and P53 gene deletion. 30 patients with B-CLL were enrolled in the trial from 2 centers in Cairo, Egypt during the period May 2000 to January 2002. Karyotyping and FISH assessment for possible chromosomal abnormalities [trisomy 12, Rh 1 gene and P53 gene] were done at initial diagnosis. Results of cytogenetic abnormalities were correlated with clinical picture and survival. The median age was 57.4 years [range 40-75]. Karyotyping technique showed that no metaphase could be detected in 30%, metaphase with normal karyotyping was observed in 63% and cytogenetic abnormalities were detected in 2 cases [1 trisomy 12 and 1 deletion in chromosome 13]. FISH examination of interphase and metaphase nuclei revealed cytogenetic abnormalities in 15 cases [50%], trisomy 12 in 9 [30%], Rb 1 gene deletion in 5 [17%] and P53 gene deletion in 1. At diagnosis, patients with trisomy 12 were significantly associated with advanced stage and absolute lymphocyte count of >/= 30,000/mm[3]. Univariate analysis showed that absolute lymphocyte count >/= 30,000/mm[3] [p=0.004] and trisomy 12 [p=.024] were associated with poor progression free survival. Interphase and metaphase FISH studies improve the cytogenetic diagnosis of chromosomal abnormalities in B-CLL. Lymphocytosis and trisomy 12 might be a good indicator of poor prognosis
Assuntos
Humanos , Masculino , Feminino , Análise Citogenética , Cariotipagem , Hibridização in Situ Fluorescente , Aberrações Cromossômicas , Genes p53 , PrognósticoRESUMO
This is a retrospective study that included 54 patients with malignant pleural mesothelioma presenting to NEMROCK from 1999 to 2001. Twenty- six patients [group I] were treated with platinol-adriamycin, 16 patients [group II] were treated with holoxan-adriamycin and 12 patients [group III] were treated with external beam radiation therapy. The overall response rate in the three treatment groups were 38.5%, 43.8% and 25%, respectively. The median overall survival of cases of the whole study was 7.5 months. Eighteen patients from groups I and II received salvage radiation therapy when they progressed. Their response rate to radiation therapy was 33.3%. The overall median survival of these patients was 10.5 months. So, radiation therapy gave a survival advantage when given as bimodality treatment following chemotherapy. The local recurrence rate was 16.6% with no cases of local recurrence encountered in patients receiving local radiation therapy. So, prophylactic radiation therapy to scar regions can reduce local recurrence. Age <50 years and epithelial pathology were significant predictors of treatment response
Assuntos
Humanos , Masculino , Feminino , Pleura , Taxa de Sobrevida , Estadiamento de Neoplasias , Metástase Neoplásica , Resultado do Tratamento , Estudos Retrospectivos , Neoplasias Pleurais/radioterapiaRESUMO
This study was done at NEMROCK and other private as well as official governmental oncology centers, where 30 patients with residual or relapsed high grade gliomas received temozolomide at a dose of 200 mg/m2/day for five successive days to be recycled on day 21 for a total of six courses. Drug administration was quite safe with accepted toxicity profiles. The response parameters, including partial response, stationary disease and progressive neoplastic process, were documented in 33%, 45% and 22%, respectively
Assuntos
Humanos , Masculino , Feminino , Recidiva/efeitos adversos , Antineoplásicos Alquilantes , Glioblastoma , Astrocitoma , Tomógrafos Computadorizados , Resultado do Tratamento , Gerenciamento ClínicoRESUMO
Twenty-three eligible patients with locally recurrent cervical carcinoma after radical hysterectomy were treated with concomitant cisplatin/paclitaxel and radiation. Thechemotherapy regimen consisted of cisplatin [20 mg/m2] and paclitaxel [45 mg/m2 therapy] that were given every other week concomitantly with 65-70 Gy local pelvic irradiation over 7 weeks. Eight patients [34.8%] experienced grade 3-4 acute toxicity during treatment. Late morbidity was reported in 4 patients [17.4%]. The chemotherapy related morbidity included mainly hematological toxicity, nausea and vomiting and neurotoxicity. The radiation related morbidity included mainly skin reaction, prostatitis and cystitis. Objective response was achieved in 69.7% ofpatients [34.8% complete response and 34.8% partial response]. The median duration of follow up for whole group was 17.1 months. Sex patients [26.9%] were alive with no evidence of disease with a median survival of 30.6 months. The 2 year overall survival was 26.9%. Five patients [21.7%] developed distant metastases. There was a tendency towards better results for earlier initial stage of the disease, patients older than 50 years old, squamous cell carcinoma tumors, tumors < 5 cm, central pelvis tumors and disease free interval from initial surgery more than 1 year. The study concluded that concomitant cisplatin/paclitaxel and radiation is a safe and tolerable treatment with reasonable response rate and satisfying survival for locally recurrent cancer cervix. However, this regimen must be run on a larger number of patients with a longer follow up period to get significant predictors of the response and survival and to guide in identifying the subset of patients that may benefit from more aggressive therapy